



**CUMBERLAND EMERGING TECHNOLOGIES EXPANDS
DOWNTOWN LIFE SCIENCES CENTER**

Incubator filled to capacity with signing of Encapsula NanoSciences

NASHVILLE, TENN (September 12, 2005) - Cumberland Emerging Technologies, Inc. (CET), a company formed to bring early-stage biomedical technologies and products from our region to the marketplace, has announced plans to expand its life sciences incubator. The CET Life Sciences Center is located in downtown Nashville, adjacent to the Union Station Hotel and across from the Frist Center for the Visual Arts.

The expansion will involve the improvement of approximately 5,400 square feet into laboratory and research space. Construction is expected to be completed this year. Up to 20,000 square feet at the facility is available to CET for potential development.

The center's original space is now filled to capacity with the signing of CET's eighth tenant, Encapsula NanoSciences. Founded by Vanderbilt graduate Dr. Zahra MirAfzali, Encapsula



produces liposomes for research labs in universities and biotechnology companies. Liposomes, which are microscopic structures used to deliver drugs, genes and other substances to cells and organs, are in great demand by research labs; however, producing them can be extremely time-consuming. For this reason, many labs choose to outsource this function. Encapsula is

focused on developing liposomes that target cells more effectively, which could lead to significant advancement in drug delivery systems in the foreseeable future.

"We are very excited to move forward with the growth and development of the CET Life Sciences Center," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals and CET. "The facility continues to attract early-stage biotech companies like Encapsula who are interested not only in shared laboratory space, equipment and infrastructure, but also in locating close to sources of research and expertise."

-- more --

“For most young biotechnology companies, availability of suitable laboratory and research space is a key consideration,” said Chris McKinney, Director of the Office of Technology Transfer and Enterprise Development at Vanderbilt University. “We believe CET’s expansion will be a tremendous asset to Vanderbilt researchers who require such space to proceed with their entrepreneurial ventures.”



The incubator project complements efforts of both the Nashville Chamber of Commerce and the Mayor’s office to expand downtown development in Nashville, and is designed to alleviate the current shortage of laboratory space in the Metro area.

“This opportunity to further develop the biotech industry in Nashville is a natural expansion of the city’s dynamic health care industry,” said Matt Gallivan, President of the Nashville Health Care Council. “The infrastructure provided by CET’s Life Sciences Center is a key component to fostering the growth of young biotechnology and life sciences companies in the area which, without such support, might never see their ideas develop into commercial success and, most importantly, patient use.”

Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint initiative between Vanderbilt University, Cumberland Pharmaceuticals Inc. and the Tennessee Technology Development Corporation (TTDC). The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the commercial marketplace. CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.

* * *